|
Telik, Inc. of Palo Alto, CA is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced investigational drug candidates in clinical development are TELINTRA® (Ezatiostat HCl, TLK199) for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA® (Canfosfamide HCl, TLK286) for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates.
 Needham & Co. Biotechnology and Medical Technology Conference
June 11, 2008
10:00 am EDT (7:00 am PDT)
Click here for the webcast,
Click here for the presentation.
June 10, 2008
Telik Announces Patents on Compounds Related to TELINTRA
June 5, 2008
Telik Announces Presentation and Webcast at Needham Biotechnology Conference
April 9, 2008
The Wall Street Transcript Interview with Dr. Michael Wick and Cynthia Butitta
March 7, 2008
CEOCFO Interview with Dr. Michael Wick and Cynthia Butitta
|
